Open AccessInhibition effects of a natural inhibitor on RANKL downstream cellular signalling cascades cross‐talking
Author(s) -
Wang Biao,
Hao Dingjun,
Zhang Zhen,
Gao Wenjie,
Pan Hu,
Xiao Yuan,
He Baorong,
Kong Lingbo
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13703
Subject(s) - rankl , chemistry , mapk/erk pathway , p38 mitogen activated protein kinases , osteoclast , luteolin , phosphorylation , nitric oxide , protein kinase b , signal transduction , nf κb , reactive oxygen species , western blot , microbiology and biotechnology , pharmacology , flavonoid , biochemistry , receptor , biology , activator (genetics) , antioxidant , organic chemistry , gene
Myricitrin is a natural occurring flavonoid glycoside that possesses effects on inhibiting nitric oxide ( NO ) transmission and preventing inflammatory reaction. Although previous study showed the myricitrin possesses antibone loss effects via reducing the expression of IL ‐6 and partially suppressing reactive oxygen species ( ROS ) production. However, the effects of myricitrin on nuclear factor‐kappaB ligand ( RANKL )‐stimulated osteoclastogenesis have not yet been further investigated. The current study was aimed to demonstrating the inhibitory effects of myricitrin on RANKL ‐stimulated osteoclastogenesis and relevant mechanisms. We found myricitrin significantly suppressed osteoclastogenesis suggesting that it may acts on RANKL / RANK induced downstream signal cross cascading in osteoclast precursors. In that, our Western blotting results showed myricitrin significantly attenuated RNAKL / MAPK s (phosphorylation of p38, ERK , JNK ) and AKT signal cascading. Complementing previous study, our results suggesting as a natural inhibitor, myricitrin possesses the potential therapeutic effects on inflammatory osteolysis.